COMMUNIQUÉS West-GlobeNewswire

Avalo Reports 2023 Financial Results and Provides Business Updates
29/03/2024
Acquired AVTX-009, Phase-2 ready anti-IL-1β mAb, in March 2024 Increased cash position with private placement financing in March 2024 providing up to $185 million, including initial upfront investment of $115.6 million [...]
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results
29/03/2024
– Recent end-of-Phase 2 meeting with FDA resulted in alignment on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine – – Topline data from [...]
Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
29/03/2024
VIP236, first-in-class small molecule-drug conjugate (SMDC), preliminary Phase 1 data and update on pipeline progress will be presented by management at a virtual investor event on April 8 at 2:00 PM PT Phase 1 trial [...]
Range Impact Reports 4Q 2023 and Full Year 2023 Financial Results
29/03/2024
CLEVELAND, OHIO, March 29, 2024 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTC: RNGE) (“Range Impact”), a public impact investing company dedicated to acquiring, reclaiming and repurposing mine sites in Appalachia, [...]
NMDP Cycle Kicks Off Nationwide Cycling Events Giving Hope to Patients in Need of a Blood Stem Cell Transplant
29/03/2024
Riders can select from six routes to help raise funds and bring awareness to NMDP’s lifesaving mission MINNEAPOLIS, March 29, 2024 (GLOBE NEWSWIRE) -- NMDP SM Cycle (formerly Be The Match® Tour de TC) kicks off March 30 [...]
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
29/03/2024
- Data for masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) highlight best-in-class therapeutic index and demonstrate clinical benefits in metastatic microsatellite-stable (MSS) colorectal cancer (CRC) with higher, more [...]
Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates
29/03/2024
ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual Meeting 2024 ELI-007 and ELI-008 preclinical data were accepted for a poster presentation at the AACR Annual Meeting [...]
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update
29/03/2024
AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of [...]
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
29/03/2024
-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 -- -- Exploring opportunities to expand KPI-012 into additional corneal indications -- -- Cash resources as of [...]
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update
29/03/2024
NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business [...]
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
29/03/2024
Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results March 29, 2024 SAB-142 Phase 1 trial on track for data release during 2024 Completed [...]
Vision Sensing Acquisition Corp. Announces Intention to Extend Period to Consummate Initial Business Combination to May 3, 2024
29/03/2024
MIAMI, March 29, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”) a special purpose acquisition company, announced today that it has notified Continental Stock [...]
Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2023
29/03/2024
Viactiv ® Product Line Generated Net Revenues of Approximately $11.9 Million for the Year Ended December 31, 2023, an Increase of Approximately 12% as Compared to the Year Ended December 31, 2022 HOUSTON, TEXAS, March [...]
Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development
29/03/2024
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the [...]
BioSenic S.A. : Information on the total number of voting rights and shares
29/03/2024
PRESS RELEASE – REGULATED INFORMATION Mont-Saint-Guibert, Belgium, March 29, 2024, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and [...]
BioSenic S.A. : Information relative au nombre total de droits de vote et d’actions
29/03/2024
COMMUNIQUE DE PRESSE – INFORMATION REGLEMENTEE Mont-Saint-Guibert, Belgique, le 29 mars 2024 à 07h00 CEST – BIOSENIC (Euronext Bruxelles et Paris: BIOS), la société en phase clinique spécialisée dans les maladies auto- [...]
Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates
29/03/2024
SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery [...]
Trinity Biotech plc to Announce Q4 and Fiscal Year 2023 Financial Results
28/03/2024
Conference Call Scheduled for Thursday, April 4, 2024 at 8:00 AM ET DUBLIN, Ireland, March 28, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of [...]
Predictive Oncology Reports Year End 2023 Financial Results and Provides Business Update
28/03/2024
Company to host investor call and webcast on Monday, April 1st, at 8:30am EDT PITTSBURGH, March 28, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) , a science driven company leveraging its proprietary [...]

Pages